KinSea Lead Discovery AS is a preclinical biotechnology company focused on the discovery and development of small-molecule therapeutics derived from marine bioactive compounds. The company uses marine natural product discovery, medicinal chemistry, and drug development approaches to identify and optimize novel drug candidates, with an initial focus on oncology programs including FLT3 inhibitors for acute myeloid leukemia (AML) and other hematologic malignancies.